12:00 AM
 | 
Jul 23, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/20 cls
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Piper Jaffray Edward Tenthoff Price target Neutral 0% $15.68
Tenthoff raised his target to $14 from $11.50 after Infinity regained ex-U.S. rights to IPI-145, an oral delta and gamma inhibitor of phosphoinositide 3-kinase (PI3K). Last week, Infinity restructured a 2008 deal with Purdue Pharma L.P. and its affiliate Mundipharma International Ltd. to regain rights to its PI3K, fatty acid amide hydrolase (FAAH) and early discovery programs (see B4). He now values IPI-145 at $250M after adding back ex-U.S. rights, up from $150M. IPI-145 is in Phase I testing for advanced hematologic malignancies, with Phase II trials in asthma and rheumatoid arthritis (RA) slated to start this half.
Isis Pharmaceuticals Inc. (NASDAQ:ISIS) Jefferies Eun Yang Downgrade Underperform (from buy) -3% $12.97
Yang maintained her $10 target after a "significant recent run-up" in Isis shares "despite...

Read the full 972 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >